Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novartis And Vertex Win Key FDA Approvals

by Lisa M. Jarvis
July 13, 2015 | A version of this story appeared in Volume 93, Issue 28

Two highly anticipated new drugs have gotten FDA’s green light. The agency approved Vertex Pharmaceuticals’ Orkambi to treat people whose cystic fibrosis is driven by a mutation in the ΔF508 gene. And it okayed Novartis’s heart failure pill Entresto, which combines the active ingredient in the older heart drug Diovan with the neprilysin inhibitor sacubitril. Both new drugs are key to their marketers’ future. Vertex has priced Orkambi at $259,000 per year and expects peak annual sales of more than $4 billion. Novartis, which sees Entresto’s sales passing $5 billion, set an initial price of roughly $4,500 per year. But the firm says it may charge insurers more if the drug keeps heart failure patients out of the hospital.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.